» Articles » PMID: 3948454

Age-associated Changes in Ceftriaxone Pharmacokinetics

Overview
Specialty Pharmacology
Date 1986 Jan 1
PMID 3948454
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Ceftriaxone pharmacokinetic parameters were compiled from recent publications. The subjects (27 female, 93 male) were from 1 day to 92 years old and appeared to have normal renal and hepatic function. In 1- to 8-day-old neonates, the half-life averaged 19 hours; it declined to 6.3 hours in 1- to 6-year-old subjects and then increased gradually throughout the remainder of the life-span to 14 hours in 75- to 92-year-old subjects. The age-associated changes in half-life appeared to result from changes in systemic clearance. The fraction of the dose eliminated renally averaged 70% in neonates and declined throughout childhood to 40 to 60% in adults, in whom it was age invariant. No clinically significant differences between males and females were detected in ceftriaxone kinetic parameter values. Plasma protein binding of ceftriaxone (100 mg/L) was about 70% in neonates and it increased throughout childhood to the adult value of 90 to 95%. To achieve a given free concentration of ceftriaxone, the same dosage per unit surface area can be used for children and adults, provided glomerular filtration and biliary secretion function are normal for age. Dosage should be reduced by as much as a factor of 5 in neonates less than 1 week of age and perhaps by a factor of 2 in the very old.

Citing Articles

Ceftriaxone as a Novel Therapeutic Agent for Hyperglutamatergic States: Bridging the Gap Between Preclinical Results and Clinical Translation.

Abulseoud O, Alasmari F, Hussein A, Sari Y Front Neurosci. 2022; 16:841036.

PMID: 35864981 PMC: 9294323. DOI: 10.3389/fnins.2022.841036.


Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.

Hartman S, Upadhyay P, Hagedoorn N, Mathot R, Moll H, van der Flier M Clin Pharmacokinet. 2021; 60(10):1361-1372.

PMID: 34036552 PMC: 8505376. DOI: 10.1007/s40262-021-01035-9.


Is Once-Daily High-Dose Ceftriaxone plus Ampicillin an Alternative for Enterococcus faecalis Infective Endocarditis in Outpatient Parenteral Antibiotic Therapy Programs?.

Herrera-Hidalgo L, de Alarcon A, Lopez-Cortes L, Luque-Marquez R, Lopez-Cortes L, Gutierrez-Valencia A Antimicrob Agents Chemother. 2020; 65(1).

PMID: 33046488 PMC: 7927845. DOI: 10.1128/AAC.02099-20.


Prediction of Unbound Ceftriaxone Concentration in Children: Simple Bioanalysis Method and Basic Mathematical Equation.

Kan M, Shi H, Han B, Wu Y, Li Q, Guo Z Antimicrob Agents Chemother. 2020; 65(1).

PMID: 33020163 PMC: 7927823. DOI: 10.1128/AAC.00779-20.


Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions.

Ba B, Gaudin K, Desire A, Phoeung T, Langlois M, Behl C Antimicrob Agents Chemother. 2018; 62(12).

PMID: 30348664 PMC: 6256799. DOI: 10.1128/AAC.01170-18.


References
1.
Hallynck T, Soep H, Thomis J, Boelaert J, DANEELS R, DETTLI L . Should clearance be normalised to body surface or to lean body mass?. Br J Clin Pharmacol. 1981; 11(5):523-6. PMC: 1401592. DOI: 10.1111/j.1365-2125.1981.tb01163.x. View

2.
Du Bois D, Du Bois E . A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989; 5(5):303-11; discussion 312-3. View

3.
Martin E, Koup J, Paravicini U, Stoeckel K . Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr. 1984; 105(3):475-81. DOI: 10.1016/s0022-3476(84)80032-3. View

4.
Schwartz G, Feld L, Langford D . A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984; 104(6):849-54. DOI: 10.1016/s0022-3476(84)80479-5. View

5.
Schaad U, Stoeckel K . Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother. 1982; 21(2):248-53. PMC: 181867. DOI: 10.1128/AAC.21.2.248. View